Whitepaper: 21 CFR Part 11 Compatible Software for NucleoCounter® NC-3000™

Is your data secure? In this whitepaper, you will learn how to maintain compliance with the FDA’s 21 CFR Part 11 regulation using the NucleoCounter® NC-3000™ system. This comprehensive guide explains each part of the regulation and outlines specific actions you can take as an NC-3000™ user to ensure compliance.

This whitepaper also details how the NC-3000™’s software, NucleoView™ NC-3000™, is designed to simplify compliance. We provide examples of the Audit Trail, which tracks all activities recorded by the software, ensuring complete traceability. Learn about the different user levels and how the instrument ensures data integrity and security.

With this whitepaper and our user guide, you will gain a solid understanding of 21 CFR Part 11 and learn what is required to build a compliant cell analysis system in your production facility.

Request Whitepaper

I hereby provide my consent *

DISCLAIMER: This service is for orientation purposes only. ChemoMetec only will provide you with details about product changes if such have a significant impact on product form, fit or function. ChemoMetec A/S shall not be held liable for any damage resulting from errors or oversights resultant of the service. Users should make independent decisions regarding the completeness of the information based on all sources available. ChemoMetec A/S reserves the right to introduce changes to products to incorporate new technology. Read more about how we collect, use, disclose, and safeguard your information, Privacy Policy.

DISCLAIMER

We welcome and encourage blog users to leave comments. ChemoMetec reserves the right to moderate all comments and delete any that could be determined as i) irrelevant, ii) containing spam, iii) containing profanity, iv) deemed offensive or v) containing questionable content. We reserve the right to withhold any comment from being published. ChemoMetec is not responsible for the content in comments, which represent solely the views of the commenter.

0 Comments